14.79
+0.92(+6.63%)
Currency In USD
| Previous Close | 13.87 |
| Open | 13.83 |
| Day High | 14.96 |
| Day Low | 13.65 |
| 52-Week High | 47.45 |
| 52-Week Low | 13.24 |
| Volume | 1.75M |
| Average Volume | 1.65M |
| Market Cap | 1.51B |
| PE | -4.13 |
| EPS | -3.58 |
| Moving Average 50 Days | 22.78 |
| Moving Average 200 Days | 31.5 |
| Change | 0.92 |
If you invested $1000 in Dyne Therapeutics, Inc. (DYN) since IPO date, it would be worth $618.83 as of February 05, 2025 at a share price of $14.79. Whereas If you bought $1000 worth of Dyne Therapeutics, Inc. (DYN) shares 3 years ago, it would be worth $2,155.98 as of February 05, 2025 at a share price of $14.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 03, 2025 12:30 PM GMT
WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven disease
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
GlobeNewswire Inc.
Jan 21, 2025 12:30 PM GMT
- Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 - WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transformi
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026
GlobeNewswire Inc.
Jan 10, 2025 11:30 AM GMT
- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust and sustained functional improvements; potential t